113 related articles for article (PubMed ID: 28350209)
21. The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.
Baranov MV; Bianchi F; van den Bogaart G
Cells; 2020 Dec; 10(1):. PubMed ID: 33375410
[TBL] [Abstract][Full Text] [Related]
22. Loss of PIKfyve drives the spongiform degeneration in prion diseases.
Lakkaraju AKK; Frontzek K; Lemes E; Herrmann U; Losa M; Marpakwar R; Aguzzi A
EMBO Mol Med; 2021 Sep; 13(9):e14714. PubMed ID: 34291577
[TBL] [Abstract][Full Text] [Related]
23. Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations.
Ikonomov OC; Sbrissa D; Shisheva A
Toxicol Appl Pharmacol; 2019 Nov; 383():114771. PubMed ID: 31628917
[TBL] [Abstract][Full Text] [Related]
24. Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.
Jahangiri S; Friedberg J; Barr P
Expert Opin Emerg Drugs; 2014 Sep; 19(3):367-83. PubMed ID: 24960458
[TBL] [Abstract][Full Text] [Related]
25. Curcumin targets the TFEB-lysosome pathway for induction of autophagy.
Zhang J; Wang J; Xu J; Lu Y; Jiang J; Wang L; Shen HM; Xia D
Oncotarget; 2016 Nov; 7(46):75659-75671. PubMed ID: 27689333
[TBL] [Abstract][Full Text] [Related]
26. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
Pongas G; Cheson BD
Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
[TBL] [Abstract][Full Text] [Related]
27. Selective elimination of pluripotent stem cells by PIKfyve specific inhibitors.
Chakraborty AR; Vassilev A; Jaiswal SK; O'Connell CE; Ahrens JF; Mallon BS; Pera MF; DePamphilis ML
Stem Cell Reports; 2022 Feb; 17(2):397-412. PubMed ID: 35063131
[TBL] [Abstract][Full Text] [Related]
28. A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.
Cooper AC; Karp RM; Clark EJ; Taghizadeh NR; Hoyt JG; Labenski MT; Murray MJ; Hannig G; Westlin WF; Thompson CD
Clin Cancer Res; 2006 Apr; 12(8):2583-90. PubMed ID: 16638869
[TBL] [Abstract][Full Text] [Related]
29. The Phosphoinositide-Gated Lysosomal Ca(2+) Channel, TRPML1, Is Required for Phagosome Maturation.
Dayam RM; Saric A; Shilliday RE; Botelho RJ
Traffic; 2015 Sep; 16(9):1010-26. PubMed ID: 26010303
[TBL] [Abstract][Full Text] [Related]
30. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling.
Cai X; Xu Y; Cheung AK; Tomlinson RC; Alcázar-Román A; Murphy L; Billich A; Zhang B; Feng Y; Klumpp M; Rondeau JM; Fazal AN; Wilson CJ; Myer V; Joberty G; Bouwmeester T; Labow MA; Finan PM; Porter JA; Ploegh HL; Baird D; De Camilli P; Tallarico JA; Huang Q
Chem Biol; 2013 Jul; 20(7):912-21. PubMed ID: 23890009
[TBL] [Abstract][Full Text] [Related]
31. Reactive oxygen species prevent lysosome coalescence during PIKfyve inhibition.
Saffi GT; Tang E; Mamand S; Inpanathan S; Fountain A; Salmena L; Botelho RJ
PLoS One; 2021; 16(11):e0259313. PubMed ID: 34813622
[TBL] [Abstract][Full Text] [Related]
32. Melatonin antagonizes cadmium-induced neurotoxicity by activating the transcription factor EB-dependent autophagy-lysosome machinery in mouse neuroblastoma cells.
Li M; Pi H; Yang Z; Reiter RJ; Xu S; Chen X; Chen C; Zhang L; Yang M; Li Y; Guo P; Li G; Tu M; Tian L; Xie J; He M; Lu Y; Zhong M; Zhang Y; Yu Z; Zhou Z
J Pineal Res; 2016 Oct; 61(3):353-69. PubMed ID: 27396692
[TBL] [Abstract][Full Text] [Related]
33. Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
Choe H; Ruan J
Oncology (Williston Park); 2016 Sep; 30(9):847-58. PubMed ID: 27633417
[TBL] [Abstract][Full Text] [Related]
34. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
35. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
36. Classification of non-Hodgkin lymphoma in South-eastern Europe: review of 632 cases from the international non-Hodgkin lymphoma classification project.
Dotlic S; Perry AM; Petrusevska G; Fetica B; Diebold J; MacLennan KA; Müller-Hermelink HK; Nathwani BN; Boilesen E; Bast M; Armitage JO; Weisenburger DD
Br J Haematol; 2015 Nov; 171(3):366-72. PubMed ID: 26213902
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of PIKfyve by YM-201636 dysregulates autophagy and leads to apoptosis-independent neuronal cell death.
Martin S; Harper CB; May LM; Coulson EJ; Meunier FA; Osborne SL
PLoS One; 2013; 8(3):e60152. PubMed ID: 23544129
[TBL] [Abstract][Full Text] [Related]
38. Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control.
Wible DJ; Parikh Z; Cho EJ; Chen MD; Mukhopadhyay S; Dalby KN; Varadarajan S; Bratton SB
bioRxiv; 2023 Mar; ():. PubMed ID: 36993747
[TBL] [Abstract][Full Text] [Related]
39. B-cell receptor pathway modulators in NHL.
Blum KA
Hematology Am Soc Hematol Educ Program; 2015; 2015():82-91. PubMed ID: 26637705
[TBL] [Abstract][Full Text] [Related]
40. Toll-like receptor 9 trafficking and signaling for type I interferons requires PIKfyve activity.
Hayashi K; Sasai M; Iwasaki A
Int Immunol; 2015 Sep; 27(9):435-45. PubMed ID: 25925170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
